The single-state companies involved in the merger are anticipated to continue their operations independently with the support of Vireo.
A recent press release announced a merger between the independent cannabis company Proper Brands and multi-state parent company Vireo Growth Inc (1). The $397 million series of all-stock transactions will expand the operation reach of Vireo Growth, which is also acquiring three other companies in the merger, while Proper Brands will maintain its established identity and leadership in Missouri (2).
Vertically integrated, Missouri-based Proper Brands currently operates 11 dispensaries in the state, where both medical and recreational cannabis are legal (3). It cultivates over 100 strains of cannabis and also operates two manufacturing facilities. “We’re building a bigger family,” stated John Pennington, founder and CEO of Proper, in the press release. “This merger brings together the best local operators who share our values and passion. While this is a new chapter, our commitment to serving Missouri customers, employees and communities remains our top priority.”
The multi-brand company offers flower, pre-rolls, vaporizers, concentrate, edibles, and tinctures at its retail locations. “Proper remains unwavering in delivering what our passionate customers want: quality cannabis flower and extracts, as well as consistent, delicious edibles,” added Matt LaBrier, COO and co-founder of Proper, in the press release. “With this merger, we will have access to a larger pool of industry experts for best practices and joint resources to continue expanding Proper Brands’ portfolio of products for adult-use consumers and medical cannabis patients across Missouri.”
Founded in 2014, Vireo Growth currently operates 16 retail locations across the nation and on December 18 announced it had acquired four single state cannabis operators, including Proper Brands (2). The other brands in the merger are Deep Roots Harvest and WholesomeCo Cannabis, which expands Vireo’s operations to Nevada and Utah. Additionally, the company signed a binding Memorandum of Understanding to acquire The Flowery, located in Florida, bringing the total states in which it operates to seven, its dispensaries to 48, and its cultivation facilities to nine, covering 1,043,500 square feet of cultivation and manufacturing space. The merger also includes Arches, a cannabis delivery and analytics platform.
Vireo estimates 2024 proforma revenue of approximately $394 million and EBITDA of approximately $94 million.
Also announced in the news release, John Mazarakis was appointed CEO and Co-Executive Chairman, and Tyson Macdonald was appointed CFO. “I am thrilled to become Vireo’s Chief Executive Officer and to unveil a new strategy in the management and development of leading U.S. cannabis assets upon completion of the merger,” stated Mazarakis, in the news release. “We are proud to introduce a new platform for operators to continue growing their businesses independently, embracing a decentralized approach that empowers local knowledge and expertise to flourish. We also look forward to supporting this network of partners with complementary shared corporate services and the proprietary Arches technology platform which will enable their companies to adapt quickly to consumer behavior and capture incremental market share.”
References
Ep 24, Part II: Data Transparency in Cannabis Testing with Yasha Khan
December 12th 2024Evan Friedmann and Yasha Kahn, co-founder of MCR Labs, discuss the discrepancies between current regulations and data on mycotoxins and pesticides in cannabis products. They highlight the need for updated regulations based on new data, emphasizing the importance of accurate testing and labeling. They also discuss the issue of result manipulation, particularly in THC content, and the need for public health officials to address this. Yasha suggests making testing data public to enhance oversight and suggests a national entity to manage this data for better consistency and public safety.
Ep 24, Part I: Data Transparency in Cannabis Testing with Yasha Khan
November 21st 2024Evan Friedmann interviews Yasha Khan, co-founder of MCR Labs, about his journey into the cannabis industry and his efforts to promote transparency and integrity in laboratory practices. Yasha discusses the origins of MCR Labs, which began in Massachusetts to meet the needs of the soon-to-be legal medical cannabis market. He explains the challenges faced, including result manipulation by labs and the impact on public health. Yasha's Freedom of Information Act (FOIA) project aimed to gather testing data from 37 states, revealed significant discrepancies in potency and mold results. Despite some states' reluctance to share data, Yasha has made much of this data public, leading to collaborative research and publications on various aspects of cannabis testing.
Cannabis, US Presidential Election 2024, and Beyond: A Roundtable Discussion, Part II
December 17th 2024With the recent 2024 presidential election behind us, the future of cannabis still has many unknowns moving forward and questions still to be discussed. In this roundtable discussion with four knowledgeable industry leaders, we explore the nuanced political landscape of cannabis legalization and rescheduling in the context of the election, including state and federal policies and possible paths forward for testing standardization. Join us in the second part of a compilation of responses from Kim Anzarut, CQA, CP-FS, CEO of Allay Consulting; Susan Audino, PhD, founder of S.A. Audino & Associates, LLC; Zacariah Hildenbrand, PhD, research Professor at the University of Texas at El Paso; and David Vaillencourt, CEO of The GMP Collective.